Investment Firms Raise Estimates for Complete Genomics, Danaher | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Two investment firms today separately raised estimates for Complete Genomics and Danaher.

Oppenheimer raised its share price target for Complete Genomics to $18.50, while Jefferies increased its 2011 EPS for Danaher to $2.70 and upped its share price target for the firm.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.